20530 ⎘
Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
NEURAL REPAIR COMPOSITION, METHOD OF PREPARATION, AND USE THEREOF
#2Treatments Using Methylthioninium Salt, Liquid Mineral Blends, and/or Secondary Physiologically Active Compounds With Physiological Therapies
#3USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF PAIN, AND CORRESPONDING COMPOSITIONS
#4COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE
#5PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE
#6COMPOSITION AND PROCESS FOR A LIPID NANO-PARTICLE DELIVERY OF OXYGEN AND VITAL METABOLIC COMPOUNDS FOR HEMORRHAGIC SHOCK
#7TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
#8SYNERGISTIC COMBINATION OF NAD+ AND THERAPEUTIC PEPTIDES DELIVERED VIA IONTOPHORESIS FOR ENHANCED AND PROLONGED REGENERATIVE EFFECTS
#9TREATING ELEVATED INTRAOCULAR PRESSURE WITH NICOTINAMIDE
#10NANOPARTICLE CONSTRUCTS FOR SYSTEMIC CO-DELIVERY OF ANTI-TUMOR AGENTS
#11METHODS FOR PRODUCING CYCLIC DINUCLEOTIDES
#12NOVEL PERSONAL NEOANTIGEN VACCINES AND MARKERS
#13KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF ARTHRITIC DISEASES
#14DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION
#15DUAL STING/RIG-I AGONIST ONCOLYTIC MINICELLS AS IN SITU IMMUNIZATION AGENTS AND METHODS OF USE
#16MICROBIOTA RESTORATION THERAPY (MRT) COMPOSITIONS AND METHODS OF MANUFACTURE
#17A SYSTEM AND METHOD FOR COMPARTMENTALIZED INGREDIENTS FOR A LIQUID PHARMACEUTICAL FORMULATION
#18PHARMACEUTICAL COMBINATION AND USE THEREOF
#19COMPOSITIONS FOR PROMOTING LONGEVITY AND METHODS OF USING THE SAME
#20ANTIBODY DRUG CONJUGATES
#21NUTRACEUTICAL COMPOUNDS USEFUL IN THE TREATMENT OF CORONAVIRUS DISEASE
#22NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF
#23COMPOSITIONS AND METHODS FOR LOCAL DELIVERY OF PHARMACEUTICAL AGENTS TO TREAT CANCER
#24COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
#25OXYGEN-ENHANCED ADAPTIVE FUNCTIONAL BEVERAGE FOR ANTI-AGING AND METHOD OF PREPARATION
#26COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE
#27ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE
#28Dietary Supplement
#29POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION
#30Compositions Comprising NAD+ and Associated Methods of Treatment
#31COMPOSITIONS COMPRISING STING AGONISTS AND METHODS OF USE FOR TREATING GLIOMA
#32CELL-SPECIFIC EXPRESSION OF modRNA
#33CAP ANALOG AND USE THEREOF
#34COMBINATION THERAPY USING VPS34 INHIBITORS
#35METHOD FOR TREATING TAUOPATHY IN THE BRAIN, BRAIN STEM AND SPINAL COLUMN
#36COMPOSITION COMPRISING FLAVIN ADENINE DINUCLEOTIDE (FAD), L-GSH, ATP AND MYRISTIC ACID, ALONE OR WITH A DRUG
#37ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINES AND METHODS OF USE THEREOF
#38CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING
#39NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF
#40COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY
#41COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY
#42IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER
#43NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF
#44KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
#45IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#46BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME
#477-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES
#48NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR USE IN THE TREATMENT OF SAPHO SYNDROME
#49A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING
#50ADMINISTRATION OF STING AGONIST, CHECKPOINT INHIBITORS, AND RADIATION
#51PHARMACEUTICAL COMPOSITION CONTAINING NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) AND CD38 INHIBITOR AND APPLICATION THEREOF
#52BRANCHED OLIGONUCLEOTIDES
#53CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE
#54COMPOSITIONS AND METHODS FOR REDUCING BLOOD ALCOHOL CONTENT
#55INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF
#56LIPOSOME CARRIER-BASED MULTI-TARGET COMPLEX, DRUG DELIVERY PLATFORM CONTAINING THE SAME, AND APPLICATION THEREOF
#57Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
#58TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE
#59NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF
#60NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS
#61COMPOSITIONS FOR RAISING NAD LEVELS AND METHODS AND USES THEREOF
#62PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION
#63Synergistically Formulated Compound for Mitochondria Supplementation and Enhancement
#64DINUCLEOTIDES AND THEIR USE IN TREATING CANCER
#65SENESCENCE AND SENESCENCE ASSOCIATED SECRETORY PHENOTYPE
#66NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAME
#67COMPOSITIONS FOR SUPPLEMENTS AND RELATED METHODS
#68THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS
#69Methods of making a cyclic dinucleotide
#70METHOD FOR ENHANCING SPORTS PERFORMANCE AND ALLEVIATING SARCOPENIA WITH STREPTOCOCCUS THERMOPHILES ST7 FERMENTATION PRODUCT COMPOSITION
#71Antibody drug conjugates
#72INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT
#73Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease
#74Methods of Treating Cystic Fibrosis
#75ENGINEERING IMMUNE CHECKPOINT BLOCKADE NANOBODY-STING DELTA-TM FUSION PROTEIN AS A VERSATILE TREATMENT FOR SOLID TUMOR CANCERS
#76NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY
#77COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#78Method of Metabolic Enhancement and Composition Manufacture
#79Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs and derivatives of same
#80PREVENTION AND/OR TREATMENT OF EYE DISEASE BY COLLAGEN FIBER CROSSLINKING
#81ORAL DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) AND OTHER NUTRITIONAL SUPPLEMENTS
#82LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH SUSTAINED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF PARKINSONS DISEASE
#83STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS
#84COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#85SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY
#86NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
#87INHIBITION OF NIDOVIRUSES THAT ENCODE NSP15
#88Nucleoside derivatives and methods of use thereof
#89USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS
#90COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
#91LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF
#92METHODS FOR ENHANCING VASCULAR DENSITY
#93SILVER SALT-CONTAINING OPHTHALMIC AQUEOUS COMPOSITION FILLED IN RESIN CONTAINER
#94Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction
#95DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS
#96METHODS OF PRODUCING EXTRACELLULAR VESICLES
#97NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIA
#98Microcapsule powder stable in gastric acid, method for preparing same, and use thereof
#99SUPRACHOROIDAL DELIVERY OF DRUG PARTICLES TO REDUCE TOXICITY
#100TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#101FORMULATIONS FOR USE IN THE TREATMENT OF DIFFERENT TYPES OF ADDICTIONS AND DEPENDENCE ON ADDICTIVE SUBSTANCES
#102LIQUID COMPOSITION FOR OPHTHALMIC PRODUCT
#103NAD(H) NANOPARTICLES AND METHODS OF USE
#104TREATING MITOCHONDRIAL DNA DEPLETION DISORDERS
#105USES OF NAD+ AND/OR NAD+ INHIBITORS AND/OR NAD+ AGONISTS AND COMBINATION PREPARATION THEREOF
#106STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR
#107METHODS OF MODULATING IMMUNE ACTIVITY
#108Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column
#109TREATMENTS OF MENIERE'S DISEASE
#110ADMINISTRATION OF SPHERICAL NUCLEIC ACIDS FOR OPHTHALMOLOGICAL USES
#111NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF
#112Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
#113CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
#114PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION
#115COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES
#116USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF PAIN, AND CORRESPONDING COMPOSITIONS
#117COMPOSITIONS FOR INTRATUMORAL ADMINISTRATION AND RELATED METHODS
#118SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766
#119COMBINATION DRUG FOR TREATING MALIGNANT TUMOR, PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOR, AND PHARMACEUTICAL COMPOSITION FOR MALIGNANT TUMOR TREATMENT
#120ADMINISTRATION OF STING AGONIST AND CHECKPOINT INHIBITORS
#121HIGH CONCENTRATION INSULIN FORMULATION
#122Antibody drug conjugates
#123COMPOSITIONS COMPRISING NICOTINAMIDE ADENINE DINUCLEOTIDE-RELATED COMPOUNDS AND USE THEREOF
#124OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS
#125POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF
#126Cell-specific expression of modRNA
#127Composition for treating and/or preventing Hepatitis B virus infection and the use thereof
#128DRUG DELIVERY COMPOSITION AND A METHOD OF ADMINISTERING THE DRUG
#129Immunotherapeutic Nanoparticles And Methods Relating Thereto
#130STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF
#131IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#132ANTIBODY DRUG CONJUGATES
#1332′3′-cyclic dinucleotides and prodrugs thereof
#134DRUG DELIVERY FOR COMBINATION OF EPIGENETIC MODULATION AND IMMUNE CHECKPOINT BLOCKADE
#1353'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF
#136Cyclic dinucleotides as anticancer agents
#137Methods and Formulations for Preventing Neurological or Psychiatric Disorders
#138Cyclic di-nucleotide induction of type I interferon
#139COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE
#140Methods of Treatment, Prevention and Diagnosis
#141Compounds,compositions, and methods for the treatment of disease
#142Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
#143Inhibitors of SARM1 NADase activity and uses thereof
#144DRUG COMPOUND AND PURIFICATION METHODS THEREOF
#145COMBINATION THERAPIES OF MICROORGANISMS AND IMMUNE MODULATORS FOR USE IN TREATING CANCER
#146Pharmaceutical composition to treat health conditions associated with elevated glucose levels
#147Cyclic dinucleotides for cytokine induction
#148LYOPHILIZED PHARMACEUTICAL COMPOSITIONS
#149FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER
#150Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein
#151Compositions and methods for immune cell modulation in adoptive immunotherapies
#152STING AGONIST COMBINATION TREATMENTS WITH IMMUNE CHECKPOINT INHIBITORS
#153COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS
#154OPHTHALMIC PREPARATIONS OF MUSCARINIC AGONIST AND METHODS OF USE
#155COMPOSITIONS OF POLYMERIC MICRODEVICES AND METHODS OF USE THEREOF IN CANCER IMMUNOTHERAPY
#156PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION
#157TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
#158Compositions and methods for reducing blood alcohol content
#159COMPOSITIONS AND METHODS FOR ALTERING NEUTROPHIL MIGRATION AND METASTASIS
#160EXTRACELLULAR VESICLES COMPRISING STING-AGONIST
#161Compounds, compositions, and methods for the treatment of disease
#162NOVEL TH1-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS, AND USE OF SAME
#163Methods of modulating immune activity
#164MICROBIOTA RESTORATION THERAPY (MRT) COMPOSITIONS AND METHODS OF MANUFACTURE
#165Aldehyde functional monoterpenoids for the treatment of coronavirus infection
#166RECOMBINANT TRANSMEMBRANE DOMAIN-DEFICIENT STING AS BIOMIMETIC PROTEIN CARRIER FOR CGAMP ENHANCED CANCER IMMUNOTHERAPY
#167Methods of Modulating Activity of a Cyclic Dinucleotide (CDN) with a CDN Transporter-Modulating Agent
#168Liposomal apparatus and manufacturing methods
#169Liposomal apparatus and manufacturing methods
#170LIPOSOMAL APPARATUS AND MANUFACTURING METHODS
#171Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
#172Virus-like particles co-expressing IMC, ROP18, and MIC8, and pharmaceutical composition comprising the same
#173Cyclic di-nucleotide compounds as sting agonists
#174Methods for the treatment of bladder cancer
#175Compounds, compositions, and methods for the treatment of disease
#176AMINO ACID SALTS OF NICOTINIC ACID RIBOSIDES AS ANTI-AGING AGENTS
#177COMPOSITIONS AND METHODS FOR LOCAL DELIVERY OF PHARMACEUTICAL AGENTS TO TREAT CANCER
#178Method for Using Electrochemical Bioreactor Module with Recovery of Cofactor
#179ENHANCING ANTI-TUMOR RESPONSE IN MELANOMA CELLS WITH DEFECTIVE STING SIGNALING
#180Compounds and compositions for treating conditions associated with sting activity
#181CHITOSAN CONTAINING COMPOSITIONS AND METHODS RELATING TO SAME
#182CYCLIC DINUCLEOTIDE
#183THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS
#184Interactional Biosystem
#185Methods and Compositions for Treating Phenylketonuria
#186Antibody-drug conjugates comprising a cyclic dinucleotide
#187Use of NAD precursors for improving maternal health and/or offspring health
#188Branched oligonucleotides
#189COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
#190Compositions and methods of treating cancer with glycomimetic peptides
#191NANOPARTICLE CONSTRUCTS FOR SYSTEMIC CO-DELIVERY OF ANTI-TUMOR AGENTS
#192COMPOSITION OF ANTI-TUMOR COMPOUND DRUG AND APPLICATION THEREOF IN FIGHTING TUMORS
#193METHOD OF TREATMENT
#194CYCLIC DINUCLEOTIDES AS STING AGONISTS
#195Methods of treating the deleterious effects of excessive use of drugs and alcohol
#196A HEPATOCYTE-MIMICKING ANTIDOTE FOR ALCOHOL INTOXICATION
#197Compositions for Improved Neuroprotective Effects and Methods of Making Same
#198HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER
#199Kit for delivery of an active compound into the skin
#200Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#201Compounds for the treatment of cancer
#202Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
#203COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
#204Oligonucleotide compositions and methods for treating diseases
#205LIPOSOMAL APPARATUS AND MANUFACTURING METHODS
#206Cyclic dinucleotides for cytokine induction
#207Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
#208MODULATION OF IMMUNE RESPONSE THROUGH STIMULATOR OF INTERFERON GENES
#209Cyclic dinucleotides as anticancer agents
#210Composition for treating and/or preventing Hepatitis B virus infection and the use thereof
#211Ophthalmic solution comprising Diquafosol
#212Oligonucleotide analogues incorporating 5-aza-cytosine therein
#213Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
#214Drug compound and purification methods thereof
#215Compounds and compositions for treating conditions associated with sting activity
#216Ibandronate conjugates of nucleoside antimetabolites
#217Drug formulations
#218COMBINATION CANCER THERAPY
#219Hydrogel delivery of sting immunotherapy for treatment cancer
#220Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#221Inhibitors of SARM1 NADase activity and uses thereof
#222NADH compound composition, and preparation and use thereof
#223CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
#224In vivo delivery of oligonucleotides
#225Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#226NOVEL THERAPEUTIC STEM CELL COMPOSITIONS WITH AN ACTIVE OXIDATIVE PHOSPHORYLATION SITE AND THEIR PREPARATION
#227LYOPHILIZED PHARMACEUTICAL COMPOSITIONS
#228NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS
#229ANTIOXIDANTS FOR USE IN OPHTHALMIC SURGERY
#230MODIFICATION OF THE PH AND OTHER PHYSICAL PROPERTIES OF NICOTINAMIDE ADENINE DINUCLEOTIDE (OXIDIZED FORM) TO ALLOW FOR ENHANCED STABILITY AND MULTIPLE DELIVERY SYSTEMS
#231MODIFICATION OF THE PH AND OTHER PHYSICAL PROPERTIES OF NICOTINAMIDE ADENINE DINUCLEOTIDE (OXIDIZED FORM) TO ALLOW FOR ENHANCED STABILITY AND MULTIPLE DELIVERY SYSTEMS
#232Cyclic di-nucleotide compounds and methods of use
#233Visual function printing agent, and method for improving visual functions
#234DRUG COMBINATIONS
#235Compounds
#236Cyclic dinucleotides as sting agonists
#237Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
#238MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME
#239Compounds for the treatment of cancer
#240CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY
#241COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
#242METHODS FOR ENHANCING VASCULAR DENSITY
#243Cyclic Di-Nucleotide Induction of Type I Interferon
#244COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
#245Methods and compositions for inducing an immune response
#246Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#247Compounds,Compositions, and methods for the treatment of disease
#248Branched oligonucleotides
#249Drug vehicle compositions and methods of use thereof
#250Aqueous ophthalmic solution
#251Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache
#252Cell-specific expression of modRNA
#253Cyclic dinucleotide
#2542′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
#2552'2' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
#2563′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
#257LIPOSOMAL APPARATUS AND MANUFACTURING METHODS
#258Composition for treatment of neurodegenerative disease
#259Pan-genotypic agents against influenza virus and methods of using the same
#260Compositions and methods for immune cell modulation in adoptive immunotherapies
#261IMMUNOSTIMULATORY COMBINATIONS
#262Method for using electrochemical bioreactor module with recovery of cofactor
#263COMPOSITIONS AND METHODS FOR LIVER DISEASES
#264COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
#265Niacinamide (NAM) in ischemic tissue injury
#266COMPOSITION AND METHODS FOR CONDITIONS ASSOCIATED WITH CHRONIC PULMONARY OBSTRUCTIVE DISEASE
#267COMPOSITION AND METHODS FOR CONDITIONS ASSOCIATED WITH CHRONIC PULMONARY OBSTRUCTIVE DISEASE
#268HEALTH PROMOTING COMPOSITION AND METHODS OF USE SUPPLEMENT
#269Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
#270Cyclic dinucleotides as anticancer agents
#271Carboline derivatives or phosphorous derivatives for the treatment of muscular myopathies and traumatic injuries to muscles
#272Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
#273Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
#274Dinucleotides
#275METHODS FOR IDENTIFYING INHIBITORS OF "STIMULATOR OF INTERFERON GENE"- DEPENDENT INTERFERON PRODUCTION
#276Drug formulations
#277Cyclic dinucleotides for cytokine induction
#278Ophthalmic solution comprising diquafosol
#279Combination Therapeutic Agent For The Treatment Of Macular Degeneration
#280Method of Treating Cancer with cGAMP or cGAsMP
#281Neurochemical wellness program
#282USE OF NADPH FOR PREPARATION OF A DRUG FOR ANTIPLATELET AGGREGATION
#283Modified cyclic dinucleotide compounds
#284Nucleotide and oligonucleotide prodrugs
#285Compounds
#286Cyclic di-nucleotide compounds as STING agonists
#287Cyclic di-nucleotide compounds as sting agonists
#288Compounds for the treatment of cancer
#289Cyclic di-nucleotide compounds as STING agonists
#290Cyclic di-nucleotide compounds and methods of use
#291COMPOSITION CONTAINING NAD FOR PREVENTING AND TREATING OBESITY OR IMPAIRED GLUCOSE TOLERANCE
#292COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION
#293Method for storing P, P-bis(5′-uridyl)teraphosphate crystals
#294Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
#295Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
#296COMPOSITIONS AND METHODS FOR THE TREATMENT OF HBV INFECTION
#297Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
#298Cyclic dinucleotide compounds
#299Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
#300USE OF NADPH IN PREPARING MEDICINES FOR TREATMENT OF HEART DISEASES